|Company name||Zogenix, Inc.|
NEW YORK, October 8, 2019 – Bragar Eagel and Squire is investigating certain officers and directors of Zogenix, Inc. (NASDAQ: ZGNX) following a class action complaint that was filed against Zogenix on April 12, 2019.
The complaint alleges that throughout the class period, defendants made materially false and misleading statements regarding the company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Zogenix’s NDA for FINTEPLA contained inadequate non-clinical data and an incorrect version of a clinical dataset; (ii) consequently, Zogenix’s NDA for FINTEPLA was unlikely to gain FDA approval; and (iii) as a result, the company’s public statements were materially false and misleading at all relevant times.
If you are a long-term stockholder of Zogenix, continuously holding shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.